AnaptysBio price target lowered to $70 from $83 at Barclays

Barclays lowered the firm’s price target on AnaptysBio (ANAB) to $70 from $83 and keeps an Overweight rating on the shares. The firm says the pathogenic T-cell depletion did not translate to a benefit in ulcerative colitis. It cites the discontinuation of rosnilimab development in ulcerative colitis for the target cut.